Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2441 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
INCB059872
CAS:INCB059872: potent, oral, selective LSD1 inhibitor for myeloid leukemia research.Fórmula:C23H34N2O3Cor e Forma:SolidPeso molecular:386.536HD-TAC7
CAS:HD-TAC7 is a PROTAC HDAC degrader; IC50s: HDAC1 (3.6μM), HDAC2 (4.2μM), HDAC3 (1.1μM); reduces NF-κB p65; researched for asthma, COPD.Fórmula:C33H32FN7O7Cor e Forma:SolidPeso molecular:657.65MS8511 HCl
MS8511 HCl is a G9a/GLP inhibitor with anticancer activity that can be used in the study of a variety of cancers including brain cancer.Fórmula:C28H42ClN5O3Pureza:98.9% - 98.96%Cor e Forma:SolidPeso molecular:532.12mUNO
CAS:mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.Fórmula:C22H39N7O8SCor e Forma:SolidPeso molecular:561.652(S,R,S)-AHPC-C5-COOH
CAS:E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.Fórmula:C29H42N4O5SPureza:98%Cor e Forma:SolidPeso molecular:558.73mTOR/HDAC-IN-1
CAS:mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.Fórmula:C23H23N11O3Cor e Forma:SolidPeso molecular:501.5PROTAC SMARCA2/4-degrader-27
CAS:PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.Fórmula:C49H58FN9O6SCor e Forma:SolidPeso molecular:920.11TYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485CBP/p300-IN-14
CAS:CBP/p300-IN-14, patent WO2021213521A1's compound 27, inhibits CBP/EP300 with 3.3 nM IC50.Fórmula:C30H31F2N7O2Cor e Forma:SolidPeso molecular:559.622SIRT1/2/3-IN-1
CAS:Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.Fórmula:C46H63N9O8S2Cor e Forma:SolidPeso molecular:934.18dAURK-4
CAS:dAURK-4, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Fórmula:C52H52ClFN8O12Cor e Forma:SolidPeso molecular:1035.47NF-κB/HIF-1α-IN-1
NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.Fórmula:C24H27N7O4Cor e Forma:SolidPeso molecular:477.21245AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61MS2133
MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.Fórmula:C58H66ClF3N14O11S2Cor e Forma:SolidPeso molecular:1290.41175SW2_152F
<p>SW2_152F: Potent CBX2 ChD inhibitor, Kd 80 nM, 24-1000x selective over other CBXs in vitro.</p>Fórmula:C45H62Cl3N7O8Cor e Forma:SolidPeso molecular:935.37PROTAC SMARCA2/4-degrader-31
CAS:PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.Fórmula:C44H51N11O4Cor e Forma:SolidPeso molecular:797.95XF056-132
CAS:XF056-132 is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader [1] .Fórmula:C51H57F4N9O7SCor e Forma:SolidPeso molecular:1016.11OKI-006
CAS:OKI-006 is an oral HDAC inhibitor with potential for cancer research, derived from largazole.Fórmula:C21H30N4O5S2Cor e Forma:SolidPeso molecular:482.62Myelin Basic Protein
CAS:Myelin basic protein (MBP) is a protein believed to be important in the process of myelination of nerves in the nervous system.Fórmula:C60H103N21O17Pureza:98%Cor e Forma:SolidPeso molecular:1390.59
